Abstract:To compare the efficacy and safety of lixisenatide combined with basal insulin versus Insulin regimens for the treatment of patients with type 2 diabetes mellitus (T2DM) inadequately controlled by basal insulin. A systematic literature review was conducted in PubMed, Cochrane Library, CNKI, and WanFang database up to January 15, 2018. Randomized controlled trials (RCTs) that investigated lixisenatide combined with basal insulin, premixed insulin and basal insulin plus prandial insulin with the main meal (basal plus) or progressively covering all meals (basal-bolus) in the treatment of T2DM patients inadequately controlled by basal insulin for ≥24 weeks were identified. Taking the heterogeneity into account, network meta-analysis (NMA) using a random effect model was applied to calculate the relative risk (RR) or standardized mean difference (SMD) with 95% credibility interval (95%Crl) within a Bayesian framework. Eight RCTs involving 3,584 patients were included. NMA showed that lixisenatide combined with basal insulin had a similar reduction in HbA1c compared with basal plus (SMD=-0.23%, 95%Crl: -0.61% to 0.15%), premixed insulin (SMD=-0.12%, 95%Crl: -0.50% to 0.25%) and basal bolus (SMD=0.09%, 95%Crl: -0.31% to 0.49%). There are significant differences in the change of body weight in favor of lixisenatide combined with basal insulin compared with basal plus (SMD=-1.73kg, 95%Crl: -2.37 to -1.09kg), premixed insulin (SMD=-2.28kg, 95%Crl: -2.91 to -1.64kg), and basal bolus (SMD=-2.35kg, 95%Crl: -3.05 to -1.65kg). The relative risk of symptomatic hypoglycemia of lixisenatide combined with basal insulin was significantly lower compared with premixed insulin (RR=0.60, 95%Crl: 0.46 to 0.93) and basal bolus (RR=0.60, 95%Crl: 0.43 to 0.83), and was no significant difference compared with basal plus (RR=0.75, 95%Crl: 0.55 to 1.04). Lixisenatide combined with basal insulin showed similar HbA1c reduction to premixed insulin, basal plus and basal bolus, accompanied by a significantly lower risk of hypoglycemia and a greater body weight loss.

Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI

Real‐world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12‐month, prospective observational study

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes

Insulin Glargine/Lixisenatide Fixed-Ratio Combination (Iglarlixi) Compared With Premix Or Addition Of Meal-Time Insulin To Basal Insulin In People With Type 2 Diabetes: A Systematic Review And Bayesian Network Meta-Analysis

Glycaemic Benefit of Iglarlixi in Insulin-Naive Type 2 Diabetes Patients with High HbA1c or Those with Inadequate Glycaemic Control on Two Oral Antihyperglycaemic Drugs in the LixiLan-O Randomized Trial.

Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus

Improved Glycaemic Control and Weight Benefit with Iglarlixi Versus Insulin Glargine 100 U/mL in Chinese People with Type 2 Diabetes Advancing Their Therapy from Basal Insulin Plus Oral Antihyperglycaemic Drugs: Results from the LixiLan-L-CN Randomized Controlled Trial.

iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan‐L‐CN study

Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan

Comparison Between Insulin Degludec/liraglutide Treatment and Insulin Glargine/lixisenatide Treatment in Type 2 Diabetes: a Systematic Review and Meta-Analysis

Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

Effects of Age and Disease Duration on the Efficacy and Safety of Iglarlixi in Asian People with Type 2 Diabetes: A Post Hoc Analysis of the LixiLan-O-AP and LixiLan-L-CN Trials

Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal–bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study

Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening

Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials

COMPARATIVE EFFICACY AND SAFETY OF LIXISENATIDE AND INSULIN REGIMENS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

Efficacy And Safety Of Lixisenatide In A Predominantly Asian Population With Type 2 Diabetes Insufficiently Controlled With Basal Insulin: The Getgoal-L-C Randomized Trial

Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK

Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring